Melasma - I-Melasma
☆ Kwiziphumo zika-2022 ze-Stiftung Warentest ezivela eJamani, ukwaneliseka kwabathengi ngeModelDerm bekungaphantsi kancinci kunokubonisana nge-telemedicine ehlawulweyo.
Yimeko eqhelekileyo ebonwa kwabasetyhini baseAsia kwi-40 yabo yokuqala. Isilonda esisangqa kwifoto sisondele kwi-lentigo kune-melasma.
References
Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
Kutshanje, low-fluence Q-switched Nd:YAG (LFQSNY) laser sele idume ngokunyanga i-melasma, ngakumbi eAsia. Ukushwankathela izifundo ezahlukeneyo kwakunzima, kodwa i-LFQSNY ibonakala isebenza ngokubanzi kwaye ikhuselekile kwi-melasma xa kuthelekiswa nonyango lwesintu. Nangona kunjalo, ezinye iimeko ze-mottled hypopigmentation ziye zabikwa njengempembelelo yecala le-LFQSNY, mhlawumbi ngenxa yamandla aphezulu e-laser. Ukusetyenziswa ngokungqongqo kwe-LFQSNY kunokukhokelela kwi-hyperpigmentation ekudumbeni, ngakumbi kwiithowuni ezimnyama zolusu.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
Iingxaki ze-pigmentation zihlala zifumaneka kukhathalelo lokuqala. Iintlobo eziqhelekileyo zokuphazamiseka kwe-hyperpigmentation ziquka post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
I-Melasma ayikwazi ukusonjululwa ngonyango lwe-laser kwithuba elithile lexesha, njengoko sisifo apho i-pigment isenziwa ngokuqhubekayo. I-Tranxenemic acid inceda ekuphuculeni ukunciphisa umbala.
○ Unyango
Kwamanye amazwe (umzekelo, eJapan, eKorea), i-oral tranexamic acid ifumaneka kwi-counter kwaye iyasebenza. Ikhrimu ye-melasma ene-tranexamic acid kunye ne-azelaic acid inokuba luncedo ngokuyinxenye.
IHydroquinone inokusetyenziselwa ukunyanga i-hyperpigmentation, kodwa i-FDA yanqumamisa iimveliso ze-OTC ezine-hydroquinone ukusukela ngo-2020.
#Tranexamic acid [TRANSINO]
#Laser toning technique (low fluence QS1064 laser)
#Triluma